JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy

Elisa Gremese, Stefano Alivernini, Barbara Tolusso, Gianfranco Ferraccioli, Martin P. Zeidler

Risultato della ricerca: Contributo in rivistaArticolo in rivista

14 Citazioni (Scopus)

Fingerprint

Entra nei temi di ricerca di 'JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy'. Insieme formano una fingerprint unica.

Medicine & Life Sciences